SG10201913680PA - Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof - Google Patents
Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereofInfo
- Publication number
- SG10201913680PA SG10201913680PA SG10201913680PA SG10201913680PA SG10201913680PA SG 10201913680P A SG10201913680P A SG 10201913680PA SG 10201913680P A SG10201913680P A SG 10201913680PA SG 10201913680P A SG10201913680P A SG 10201913680PA SG 10201913680P A SG10201913680P A SG 10201913680PA
- Authority
- SG
- Singapore
- Prior art keywords
- tri
- methods
- specific binding
- specifically bind
- binding molecules
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2815—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Toxicology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462004571P | 2014-05-29 | 2014-05-29 | |
US201462008229P | 2014-06-05 | 2014-06-05 | |
US201562107824P | 2015-01-26 | 2015-01-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201913680PA true SG10201913680PA (en) | 2020-03-30 |
Family
ID=54699839
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201913680PA SG10201913680PA (en) | 2014-05-29 | 2015-05-29 | Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof |
SG11201609912TA SG11201609912TA (en) | 2014-05-29 | 2015-05-29 | Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof |
SG11201609917PA SG11201609917PA (en) | 2014-05-29 | 2015-05-29 | Tri-specific binding molecules and methods of use thereof |
SG10201913324PA SG10201913324PA (en) | 2014-05-29 | 2015-05-29 | Tri-specific binding molecules and methods of use thereof |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201609912TA SG11201609912TA (en) | 2014-05-29 | 2015-05-29 | Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof |
SG11201609917PA SG11201609917PA (en) | 2014-05-29 | 2015-05-29 | Tri-specific binding molecules and methods of use thereof |
SG10201913324PA SG10201913324PA (en) | 2014-05-29 | 2015-05-29 | Tri-specific binding molecules and methods of use thereof |
Country Status (25)
Country | Link |
---|---|
US (6) | US10633440B2 (es) |
EP (3) | EP3954703A3 (es) |
JP (5) | JP6647222B2 (es) |
KR (3) | KR20220025917A (es) |
CN (4) | CN113416252A (es) |
AP (1) | AP2016009586A0 (es) |
AU (4) | AU2015266880B2 (es) |
BR (2) | BR112016027912A2 (es) |
CA (2) | CA2950008C (es) |
CL (2) | CL2016003040A1 (es) |
EA (1) | EA035419B9 (es) |
ES (2) | ES2890079T3 (es) |
IL (2) | IL249269B (es) |
MA (1) | MA40069A (es) |
MX (3) | MX2016015479A (es) |
NZ (2) | NZ726520A (es) |
PE (2) | PE20170765A1 (es) |
PH (2) | PH12016502370A1 (es) |
PL (2) | PL3148580T3 (es) |
RU (2) | RU2718692C2 (es) |
SG (4) | SG10201913680PA (es) |
TN (1) | TN2016000525A1 (es) |
TW (5) | TWI718098B (es) |
WO (2) | WO2015184207A1 (es) |
ZA (1) | ZA201607995B (es) |
Families Citing this family (179)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9963510B2 (en) | 2005-04-15 | 2018-05-08 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
US10851178B2 (en) | 2011-10-10 | 2020-12-01 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
US10131710B2 (en) | 2013-01-14 | 2018-11-20 | Xencor, Inc. | Optimized antibody variable regions |
US10487155B2 (en) | 2013-01-14 | 2019-11-26 | Xencor, Inc. | Heterodimeric proteins |
US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
EP3620473A1 (en) | 2013-01-14 | 2020-03-11 | Xencor, Inc. | Novel heterodimeric proteins |
US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
US10968276B2 (en) | 2013-03-12 | 2021-04-06 | Xencor, Inc. | Optimized anti-CD3 variable regions |
US9701759B2 (en) | 2013-01-14 | 2017-07-11 | Xencor, Inc. | Heterodimeric proteins |
EP2970505A4 (en) | 2013-03-14 | 2016-10-19 | California Inst Biomedical Res | SPECIFIC ANTIBODIES AND USES THEREOF |
US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
AU2014232416B2 (en) | 2013-03-15 | 2017-09-28 | Xencor, Inc. | Modulation of T Cells with Bispecific Antibodies and FC Fusions |
US10519242B2 (en) | 2013-03-15 | 2019-12-31 | Xencor, Inc. | Targeting regulatory T cells with heterodimeric proteins |
US10106624B2 (en) | 2013-03-15 | 2018-10-23 | Xencor, Inc. | Heterodimeric proteins |
WO2015095392A1 (en) | 2013-12-17 | 2015-06-25 | Genentech, Inc. | Anti-cd3 antibodies and methods of use |
CA2939556A1 (en) * | 2014-02-14 | 2015-08-20 | Andrew S. Chi | Improved methods for the treatment of vascularizing cancers |
CN111410691B (zh) | 2014-03-28 | 2024-02-13 | Xencor公司 | 结合至cd38和cd3的双特异性抗体 |
SG11201607070VA (en) | 2014-05-02 | 2016-11-29 | Momenta Pharmaceuticals Inc | Compositions and methods related to engineered fc constructs |
RU2718692C2 (ru) * | 2014-05-29 | 2020-04-13 | Мэкроудженикс, Инк. | Триспецифичные связывающие молекулы, которые специфически связывают антигены множества злокачественных опухолей, и способы их применения |
TWI706960B (zh) * | 2014-09-26 | 2020-10-11 | 美商宏觀基因股份有限公司 | 能夠結合cd19和cd3的雙特異性雙抗體及其用途 |
WO2016054101A1 (en) | 2014-09-29 | 2016-04-07 | Duke University | Bispecific molecules comprising an hiv-1 envelope targeting arm |
RS60201B1 (sr) | 2014-11-14 | 2020-06-30 | Hoffmann La Roche | Antigen vezujući molekuli koji sadrže trimer liganda familije tnf |
LT3223845T (lt) | 2014-11-26 | 2021-08-25 | Xencor, Inc. | Heterodimeriniai antikūnai, kurie suriša cd3 ir cd20 |
WO2016086196A2 (en) | 2014-11-26 | 2016-06-02 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cd38 |
US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
EP3237449A2 (en) | 2014-12-22 | 2017-11-01 | Xencor, Inc. | Trispecific antibodies |
EP3245231B1 (en) | 2015-01-16 | 2020-08-12 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for ror1 |
SG11201706024YA (en) | 2015-01-26 | 2017-08-30 | Macrogenics Inc | Multivalent molecules comprising dr5-binding domains |
WO2016141387A1 (en) | 2015-03-05 | 2016-09-09 | Xencor, Inc. | Modulation of t cells with bispecific antibodies and fc fusions |
CN114751989A (zh) | 2015-03-31 | 2022-07-15 | 豪夫迈·罗氏有限公司 | 包含三聚体tnf家族配体的抗原结合分子 |
AU2016263808B2 (en) | 2015-05-21 | 2019-01-03 | Harpoon Therapeutics, Inc. | Trispecific binding proteins and methods of use |
TWI773646B (zh) | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
EP3310811B1 (en) | 2015-06-16 | 2021-06-16 | Genentech, Inc. | Anti-cd3 antibodies and methods of use |
EP3112381A1 (en) * | 2015-07-01 | 2017-01-04 | FONDAZIONE IRCCS Istituto Nazionale dei Tumori | Bispecific antibodies for use in cancer immunotherapy |
WO2017011413A1 (en) * | 2015-07-10 | 2017-01-19 | Duke University | Bispecific molecules comprising an hiv-1 envelope targeting arm |
WO2017011414A1 (en) * | 2015-07-10 | 2017-01-19 | Duke University | Bispecific molecules comprising an hiv-1 envelope targeting arm |
MX2018001227A (es) | 2015-07-30 | 2018-03-26 | Macrogenics Inc | Moleculas de union a pd-1 y metodos de uso de las mismas. |
AR106188A1 (es) | 2015-10-01 | 2017-12-20 | Hoffmann La Roche | Anticuerpos anti-cd19 humano humanizados y métodos de utilización |
CN116333125A (zh) * | 2015-10-30 | 2023-06-27 | 银河生物技术有限责任公司 | 结合死亡受体4和死亡受体5的抗体 |
WO2017072361A1 (en) | 2015-10-30 | 2017-05-04 | Nbe-Therapeutics Ag | Anti-ror1 antibodies |
US10227410B2 (en) | 2015-12-07 | 2019-03-12 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and PSMA |
UA125611C2 (uk) * | 2015-12-14 | 2022-05-04 | Макродженікс, Інк. | Біспецифічні молекули, що мають імунореактивність відносно pd-1 і ctla-4, і способи їх застосування |
CN110698560B (zh) * | 2015-12-24 | 2021-11-26 | 凯惠科技发展(上海)有限公司 | 一种tpbg抗体及其制备方法、其偶联物和应用 |
CA3011815A1 (en) | 2016-01-20 | 2017-07-27 | The Scripps Research Institute | Ror1 antibody compositions and related methods |
MX2018008934A (es) * | 2016-01-22 | 2019-03-28 | Janssen Biotech Inc | Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso. |
UY37127A (es) | 2016-02-17 | 2017-08-31 | Macrogenics Inc | Moléculas de unión a ror1, y métodos de uso de las mismas |
US20220153833A1 (en) * | 2016-03-02 | 2022-05-19 | Momenta Pharmaceuticals, Inc. | METHODS RELATED TO ENGINEERED Fc CONSTRUCTS |
EP3442574A4 (en) | 2016-04-15 | 2019-12-11 | MacroGenics, Inc. | NOVEL B7-H3 BINDING MOLECULES, THEIR ANTIBODY-MEDICINAL CONJUGATES AND METHODS OF USE |
EP3243836A1 (en) * | 2016-05-11 | 2017-11-15 | F. Hoffmann-La Roche AG | C-terminally fused tnf family ligand trimer-containing antigen binding molecules |
US11623958B2 (en) | 2016-05-20 | 2023-04-11 | Harpoon Therapeutics, Inc. | Single chain variable fragment CD3 binding proteins |
CA3024683A1 (en) | 2016-05-20 | 2017-11-23 | Harpoon Therapeutics, Inc. | Single chain variable fragment cd3 binding proteins |
AU2017268460B2 (en) | 2016-05-20 | 2023-12-14 | Harpoon Therapeutics, Inc. | Single domain serum albumin binding protein |
CA3025306A1 (en) | 2016-05-23 | 2017-11-30 | Momenta Pharmaceuticals, Inc. | Compositions and methods related to engineered fc constructs |
SG10201913326UA (en) | 2016-06-07 | 2020-02-27 | Macrogenics Inc | Combination therapy |
US10787518B2 (en) | 2016-06-14 | 2020-09-29 | Xencor, Inc. | Bispecific checkpoint inhibitor antibodies |
KR20190020341A (ko) | 2016-06-28 | 2019-02-28 | 젠코어 인코포레이티드 | 소마토스타틴 수용체 2에 결합하는 이종이량체 항체 |
CN109843918B (zh) * | 2016-07-01 | 2023-08-25 | 旁分泌疗法公司 | 用于pdgf-cc抑制的方法和组合物 |
JP2019532017A (ja) * | 2016-07-14 | 2019-11-07 | フレッド ハッチンソン キャンサー リサーチ センター | がんを治療するための異なるエピトープ結合を示す複数の二重特異性結合ドメイン構築物 |
WO2018045110A1 (en) | 2016-08-30 | 2018-03-08 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
US10793632B2 (en) | 2016-08-30 | 2020-10-06 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
WO2018053328A1 (en) * | 2016-09-16 | 2018-03-22 | Duke University | Bispecific molecules comprising an hiv-1 envelope targeting arm |
AU2017342560B2 (en) | 2016-10-14 | 2022-03-17 | Xencor, Inc. | IL15/IL15Ralpha heterodimeric Fc-fusion proteins |
US11414482B2 (en) | 2016-11-08 | 2022-08-16 | University Of Miami | Anti-secretogranin III (SCG3) antibodies and uses thereof |
US11466094B2 (en) | 2016-11-15 | 2022-10-11 | Genentech, Inc. | Dosing for treatment with anti-CD20/anti-CD3 bispecific antibodies |
CA3044659A1 (en) | 2016-11-23 | 2018-05-31 | Harpoon Therapeutics, Inc. | Prostate specific membrane antigen binding protein |
JP7215997B2 (ja) | 2016-11-23 | 2023-01-31 | ハープーン セラピューティクス,インク. | 前立腺特異的膜抗原(psma)を標的とする三重特異性タンパク質と使用方法 |
KR102630036B1 (ko) * | 2016-12-23 | 2024-01-29 | 마크로제닉스, 인크. | Adam9-결합 분자, 및 이것의 사용 방법 |
CN108264561B (zh) * | 2016-12-30 | 2021-09-10 | 惠和生物技术(上海)有限公司 | 一种结合cd19、cd3和t细胞负共刺激分子的三功能分子及其应用 |
FR3061716B1 (fr) * | 2017-01-06 | 2019-05-17 | Elsalys Biotech | Nouveaux composes ciblant le cd160 humain |
BR112019013955A2 (pt) | 2017-01-06 | 2020-02-11 | Momenta Pharmaceuticals, Inc. | Composições e métodos relacionados a construtos de fc manipulados |
AU2018219887B2 (en) | 2017-02-08 | 2024-08-15 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer |
SG11201907271PA (en) * | 2017-02-10 | 2019-09-27 | Dragonfly Therapeutics Inc | Proteins binding psma, nkg2d and cd16 |
CA3235295A1 (en) | 2017-02-20 | 2018-08-23 | Dragonfly Therapeutics, Inc. | Proteins binding her2, nkg2d and cd16 |
EP3585431A4 (en) * | 2017-02-24 | 2020-12-16 | MacroGenics, Inc. | BISPECIFIC BINDING MOLECULES CAPABLE OF BINDING TO CD137 AND TUMOR ANTIGENS, AND THEIR USES |
EP3585819A4 (en) * | 2017-02-27 | 2020-10-14 | Caerus Therapeutics, Inc. | ANTIBODY CONSTRUCTIONS AND CANCER TREATMENT METHODS |
EP3585424A4 (en) * | 2017-02-27 | 2021-01-13 | Dragonfly Therapeutics, Inc. | MULTISPECIFIC BINDING PROTEINS TARGETED BY CAIX, ANO1, MESOTHELIN, TROP2, CEA OR CLAUDIN-18.2 |
EP3589662A4 (en) | 2017-02-28 | 2020-12-30 | Harpoon Therapeutics, Inc. | INDUCTIBLE MONOVALENT ANTIGBINDING PROTEIN |
KR20200026810A (ko) | 2017-05-12 | 2020-03-11 | 하푼 테라퓨틱스, 인크. | Msln 표적화 삼중 특이적 단백질 및 사용 방법 |
JP7090347B2 (ja) | 2017-05-12 | 2022-06-24 | ハープーン セラピューティクス,インク. | メソテリン結合タンパク質 |
BR112019024654A2 (pt) * | 2017-05-23 | 2020-06-09 | Dragonfly Therapeutics Inc | proteína de ligação nkg2d, cd16 e ror1 ou ror2 |
AU2018271930A1 (en) * | 2017-05-23 | 2019-12-12 | Dragonfly Therapeutics, Inc. | A protein binding NKG2D, CD16 and a tumor-associated antigen |
MX2019013995A (es) * | 2017-05-23 | 2020-07-29 | Dragonfly Therapeutics Inc | Una proteína que se une a nkg2d, cd16 y un antígeno asociado a un tumor. |
WO2018237148A1 (en) | 2017-06-21 | 2018-12-27 | Gilead Sciences, Inc. | MULTISPECIFIC ANTIBODIES TARGETING HIV GP120 AND CD3 |
US20220002425A1 (en) * | 2017-06-25 | 2022-01-06 | Systimmune, Inc. | Guidance and navigation control proteins and method of making and using thereof |
JP2020529832A (ja) | 2017-06-30 | 2020-10-15 | ゼンコア インコーポレイテッド | IL−15/IL−15Rαおよび抗原結合ドメインを含む標的化ヘテロダイマーFc融合タンパク質 |
GB201710838D0 (en) | 2017-07-05 | 2017-08-16 | Ucl Business Plc | Bispecific antibodies |
GB201710835D0 (en) | 2017-07-05 | 2017-08-16 | Ucl Business Plc | ROR1 Antibodies |
GB201710836D0 (en) | 2017-07-05 | 2017-08-16 | Ucl Business Plc | ROR1 Car T-Cells |
EP3655435A1 (en) * | 2017-07-20 | 2020-05-27 | NBE-Therapeutics AG | Multispecific antibody product that binds to different ror1 epitopes |
KR20230008269A (ko) | 2017-08-07 | 2023-01-13 | 엔비이-테라퓨틱스 아게 | 생체 내 내성이 높은 항체 약물 결합체 |
US20200216544A1 (en) * | 2017-08-16 | 2020-07-09 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16, and egfr, hla-e, ccr4, or pd-l1 |
EA202090739A1 (ru) | 2017-10-13 | 2020-09-07 | Харпун Терапьютикс, Инк. | Белки, связывающие антиген созревания в-клеток |
SG11202003359UA (en) * | 2017-10-13 | 2020-05-28 | Harpoon Therapeutics Inc | Trispecific proteins and methods of use |
US10981992B2 (en) | 2017-11-08 | 2021-04-20 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
KR20200085828A (ko) | 2017-11-08 | 2020-07-15 | 젠코어 인코포레이티드 | 신규의 항-pd-1 서열을 사용한 이중특이적 및 단일특이적 항체 |
KR20200088440A (ko) * | 2017-11-21 | 2020-07-22 | 노파르티스 아게 | 종양-연관 항원에 대한 삼중특이성 결합 분자 및 이의 용도 |
CN109912714B (zh) * | 2017-12-12 | 2021-02-19 | 深圳宾德生物技术有限公司 | 抗cd317单克隆抗体6h2h5及其应用 |
AU2018385409A1 (en) * | 2017-12-12 | 2020-07-02 | Macrogenics Inc. | Bispecific CD 16-binding molecules and their use in the treatment of disease |
SG11202005732XA (en) | 2017-12-19 | 2020-07-29 | Xencor Inc | Engineered il-2 fc fusion proteins |
CN109957026A (zh) * | 2017-12-22 | 2019-07-02 | 成都恩沐生物科技有限公司 | 共价多特异性抗体 |
KR20200118065A (ko) | 2018-02-08 | 2020-10-14 | 제넨테크, 인크. | 이중특이적 항원-결합 분자 및 이의 사용 방법 |
US11884733B2 (en) | 2018-02-08 | 2024-01-30 | Dragonfly Therapeutics, Inc. | Antibody variable domains targeting the NKG2D receptor |
CN110129369B (zh) * | 2018-02-09 | 2023-10-13 | 上海交通大学医学院附属上海儿童医学中心 | 一种嵌合抗原受体基因工程载体、免疫细胞及其应用 |
US11685781B2 (en) | 2018-02-15 | 2023-06-27 | Macrogenics, Inc. | Variant CD3-binding domains and their use in combination therapies for the treatment of disease |
WO2019164930A1 (en) * | 2018-02-20 | 2019-08-29 | Dragonfly Therapeutics, Inc. | Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use |
CN117003874A (zh) | 2018-03-20 | 2023-11-07 | 鸿运华宁(杭州)生物医药有限公司 | Gipr抗体及其与glp-1的融合蛋白质,以及其药物组合物和应用 |
US11952424B2 (en) | 2018-03-30 | 2024-04-09 | Merus N.V. | Multivalent antibody |
CA3096052A1 (en) | 2018-04-04 | 2019-10-10 | Xencor, Inc. | Heterodimeric antibodies that bind fibroblast activation protein |
CN110357960A (zh) * | 2018-04-10 | 2019-10-22 | 广州爱思迈生物医药科技有限公司 | 抗体及抗体改造方法 |
US10654944B2 (en) * | 2018-04-10 | 2020-05-19 | Y-Biologics Inc. | Cell engaging binding molecules |
CA3097605A1 (en) * | 2018-04-17 | 2019-10-24 | Invenra Inc. | Trivalent trispecific antibody constructs |
US11524991B2 (en) | 2018-04-18 | 2022-12-13 | Xencor, Inc. | PD-1 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and PD-1 antigen binding domains and uses thereof |
CN112437777A (zh) | 2018-04-18 | 2021-03-02 | Xencor股份有限公司 | 包含IL-15/IL-15RA Fc融合蛋白和TIM-3抗原结合结构域的靶向TIM-3的异源二聚体融合蛋白 |
SG11202010235QA (en) | 2018-04-18 | 2020-11-27 | Exelixis Inc | Anti-ror antibody constructs |
EP3794027A4 (en) * | 2018-05-18 | 2022-02-09 | MacroGenics, Inc. | OPTIMIZED GP41 BINDING MOLECULES AND ASSOCIATED USES |
US11746157B2 (en) | 2018-05-24 | 2023-09-05 | Janssen Biotech, Inc. | PSMA binding agents and uses thereof |
US11845797B2 (en) | 2018-07-03 | 2023-12-19 | Marengo Therapeutics, Inc. | Anti-TCR antibody molecules and uses thereof |
WO2020033702A1 (en) * | 2018-08-08 | 2020-02-13 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and a tumor-associated antigen |
BR112021004723A2 (pt) * | 2018-09-14 | 2021-06-08 | Kindred Biosciences, Inc. | anticorpos de receptor anti-il4 para uso veterinário |
CA3114038A1 (en) | 2018-09-25 | 2020-04-02 | Harpoon Therapeutics, Inc. | Dll3 binding proteins and methods of use |
EP3854816A4 (en) | 2018-09-30 | 2022-09-07 | Jiangsu Hengrui Medicine Co., Ltd. | EXATECAN ANTI-B7H3-ANALOG ANTIBODY CONJUGATE AND ASSOCIATED MEDICAL USE |
SG11202103192RA (en) | 2018-10-03 | 2021-04-29 | Xencor Inc | Il-12 heterodimeric fc-fusion proteins |
JP2022511813A (ja) * | 2018-12-04 | 2022-02-01 | ノバルティス アーゲー | Cd3に対する結合分子及びその使用 |
KR102113302B1 (ko) * | 2018-12-24 | 2020-05-20 | 원광대학교산학협력단 | 상보성결정부 기반 조류 인플루엔자 바이러스의 h5 아형에 특이적으로 결합하는 펩티드 및 이의 용도 |
EP3906057A4 (en) * | 2019-01-04 | 2022-09-14 | Marengo Therapeutics, Inc. | ANTI-TCR ANTIBODY MOLECULES AND THEIR USES |
WO2020150282A1 (en) * | 2019-01-18 | 2020-07-23 | Askgene Pharma Inc. | Pd-l1 specific monoclonal antibodies for disease treatment and diagnosis |
CN114206442A (zh) * | 2019-01-31 | 2022-03-18 | 赛诺菲生物技术公司 | 用于治疗幼年特发性关节炎的抗il-6受体抗体 |
CN114173875A (zh) | 2019-03-01 | 2022-03-11 | Xencor股份有限公司 | 结合enpp3和cd3的异二聚抗体 |
AU2020259404A1 (en) | 2019-04-19 | 2021-09-23 | Janssen Biotech, Inc. | Methods of treating prostate cancer with an anti- PSMA/CD3 antibody |
WO2020232247A1 (en) | 2019-05-14 | 2020-11-19 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
CN116987197A (zh) * | 2019-06-20 | 2023-11-03 | 成都恩沐生物科技有限公司 | 共价多特异性抗体 |
TW202136300A (zh) * | 2019-11-06 | 2021-10-01 | 德商安美基研究(慕尼黑)公司 | 用於在增殖性疾病中使用的多靶向抗原結合分子 |
KR20220113790A (ko) | 2019-12-13 | 2022-08-16 | 제넨테크, 인크. | 항-ly6g6d 항체 및 사용 방법 |
BR112022012023A2 (pt) * | 2019-12-18 | 2022-09-06 | Janssen Biotech Inc | Materiais e métodos para estabelecer alvo biológico in vivo |
KR20230015880A (ko) * | 2020-02-20 | 2023-01-31 | 윈 테라퓨틱스, 인크. | 이중특이적 gd2 및 b7h2 결합 분자 및 사용 방법 |
BR112022016550A2 (pt) | 2020-02-21 | 2022-11-16 | Harpoon Therapeutics Inc | Proteínas de ligação a flt3 e métodos de uso |
AU2021238320A1 (en) * | 2020-03-18 | 2022-09-22 | Elanco Us Inc. | Anti-IL4 receptor antibodies for veterinary use |
WO2021231976A1 (en) | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3 |
WO2021231969A1 (en) | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Heterodimeric antibodies that bind msln and cd3 |
BR112022025381A2 (pt) | 2020-06-11 | 2023-01-24 | Provention Bio Inc | Métodos e composições para prevenir diabetes tipo 1 |
CN117730096A (zh) * | 2020-08-05 | 2024-03-19 | 蜻蜓疗法股份有限公司 | 结合nkg2d、cd16和egfr的蛋白质 |
KR102607909B1 (ko) | 2020-08-19 | 2023-12-01 | 젠코어 인코포레이티드 | 항-cd28 조성물 |
KR20230084561A (ko) * | 2020-10-12 | 2023-06-13 | 그레펙스 인코포레이티드 | Sars-cov 단백질 발현 세포로 t 세포 반응을 표적화하는 항체 작제물, 이의 설계 및 용도 |
KR20230086765A (ko) | 2020-10-13 | 2023-06-15 | 얀센 바이오테크 인코포레이티드 | 분화 클러스터 iv 및/또는 viii을 조절하기 위한 바이오-조작된 t 세포 매개 면역, 물질 및 기타 방법 |
UY39508A (es) * | 2020-11-06 | 2022-05-31 | Amgen Res Munich Gmbh | Moléculas de unión a antígeno biespecíficas con múltiples dianas de selectividad aumentada |
US20220241328A1 (en) | 2021-01-11 | 2022-08-04 | Sana Biotechnology, Inc. | Use of cd8-targeted viral vectors |
US20240059789A1 (en) | 2021-01-28 | 2024-02-22 | Janssen Biotech, Inc. | Psma binding proteins and uses thereof |
AU2022232375A1 (en) | 2021-03-09 | 2023-09-21 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cldn6 |
EP4305065A1 (en) | 2021-03-10 | 2024-01-17 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and gpc3 |
BR112023019458A2 (pt) | 2021-03-24 | 2023-12-05 | Janssen Biotech Inc | Proteínas que compreendem domínios de ligação ao antígeno de cd3 e usos dos mesmos |
CN113488112A (zh) * | 2021-06-10 | 2021-10-08 | 五邑大学 | 一种共价结合预测方法及装置 |
CN115611982B (zh) * | 2021-07-14 | 2024-05-10 | 浙江大学 | 一种抗人MICA/Bα3区的单克隆抗体及其应用 |
CN117730103A (zh) * | 2021-08-02 | 2024-03-19 | 盛禾(中国)生物制药有限公司 | 一种多特异性抗原结合蛋白及其应用 |
WO2023020315A1 (zh) * | 2021-08-19 | 2023-02-23 | 南京吉盛澳玛生物医药有限公司 | 靶向pd-l1/pd-1的抗体及其应用 |
CA3234822A1 (en) | 2021-10-28 | 2023-05-04 | Suman Kumar VODNALA | Methods for culturing cells expressing ror1-binding protein |
US20230151095A1 (en) | 2021-11-12 | 2023-05-18 | Xencor, Inc. | Bispecific antibodies that bind to b7h3 and nkg2d |
WO2023114949A1 (en) | 2021-12-16 | 2023-06-22 | Sana Biotechnology, Inc. | Methods and systems of particle production |
WO2023133595A2 (en) | 2022-01-10 | 2023-07-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
WO2023150647A1 (en) | 2022-02-02 | 2023-08-10 | Sana Biotechnology, Inc. | Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses |
US20230265218A1 (en) | 2022-02-23 | 2023-08-24 | Xencor, Inc. | Anti-cd28 x anti-psma antibodies |
WO2023164627A1 (en) | 2022-02-24 | 2023-08-31 | Xencor, Inc. | Anti-cd28 x anti-msln antibodies |
US20240059786A1 (en) | 2022-02-24 | 2024-02-22 | Xencor, Inc. | Anti-cd28 x anti-trop2 antibodies |
WO2023193015A1 (en) | 2022-04-01 | 2023-10-05 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
TW202406571A (zh) | 2022-04-13 | 2024-02-16 | 美商建南德克公司 | 莫蘇妥珠單抗之醫藥組成物及其使用方法 |
WO2023201309A1 (en) | 2022-04-13 | 2023-10-19 | Xencor, Inc. | Antibodies that bind pd-l1, pd-l2 and/or cd28 |
WO2024026377A1 (en) | 2022-07-27 | 2024-02-01 | Sana Biotechnology, Inc. | Methods of transduction using a viral vector and inhibitors of antiviral restriction factors |
WO2024027828A1 (en) * | 2022-08-05 | 2024-02-08 | Chimagen Biosciences, Ltd | Multi-specific antibodies targeting a dimerizable tumor antigen and an immunostimulatory antigen |
WO2024040195A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
WO2024044655A1 (en) | 2022-08-24 | 2024-02-29 | Sana Biotechnology, Inc. | Delivery of heterologous proteins |
WO2024059174A1 (en) * | 2022-09-14 | 2024-03-21 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
WO2024064838A1 (en) | 2022-09-21 | 2024-03-28 | Sana Biotechnology, Inc. | Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof |
WO2024064958A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
WO2024064952A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells overexpressing c-jun |
WO2024077174A1 (en) | 2022-10-05 | 2024-04-11 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
WO2024102636A1 (en) | 2022-11-07 | 2024-05-16 | Xencor, Inc. | Bispecific antibodies that bind to b7h3 and mica/b |
WO2024119157A1 (en) | 2022-12-02 | 2024-06-06 | Sana Biotechnology, Inc. | Lipid particles with cofusogens and methods of producing and using the same |
WO2024149381A1 (en) * | 2023-01-13 | 2024-07-18 | Shanghai Kaijin Biotechnology, Ltd | Multi-specific polypeptide complexes |
CN117964774A (zh) * | 2024-01-30 | 2024-05-03 | 天津大学 | 靶向IL-23和整合素α4β7的双特异性抗体及其用途 |
CN118286410B (zh) * | 2024-06-06 | 2024-09-13 | 山东兴瑞生物科技有限公司 | 一种偶联CD8抗体的肿瘤mRNA疫苗的制备方法 |
Family Cites Families (201)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5985A (en) | 1848-12-26 | Pianoforte-action | ||
US320A (en) | 1837-07-31 | John dainty | ||
US3862925A (en) | 1973-07-05 | 1975-01-28 | American Home Prod | Preparation of somatotropin release inhibiting factor and intermediates therefor |
US3842067A (en) | 1973-07-27 | 1974-10-15 | American Home Prod | Synthesis of(des-asn5)-srif and intermediates |
JPS5726506B2 (es) | 1974-03-08 | 1982-06-04 | ||
US4105603A (en) | 1977-03-28 | 1978-08-08 | The Salk Institute For Biological Studies | Peptides which effect release of hormones |
DE3378250D1 (en) | 1982-04-22 | 1988-11-24 | Ici Plc | Continuous release formulations |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
US5128326A (en) | 1984-12-06 | 1992-07-07 | Biomatrix, Inc. | Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same |
US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
US4880078A (en) | 1987-06-29 | 1989-11-14 | Honda Giken Kogyo Kabushiki Kaisha | Exhaust muffler |
US5601819A (en) | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
DE68928427T2 (de) | 1988-09-15 | 1998-06-04 | Univ Columbia | Antikörper mit modifiziertem Kohlenhydratgehalt und Verfahren zur Herstellung und Verwendung |
CA2018248A1 (en) | 1989-06-07 | 1990-12-07 | Clyde W. Shearman | Monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use |
AU6290090A (en) | 1989-08-29 | 1991-04-08 | University Of Southampton | Bi-or trispecific (fab)3 or (fab)4 conjugates |
AU6430190A (en) | 1989-10-10 | 1991-05-16 | Pitman-Moore, Inc. | Sustained release composition for macromolecular proteins |
AU642932B2 (en) | 1989-11-06 | 1993-11-04 | Alkermes Controlled Therapeutics, Inc. | Protein microspheres and methods of using them |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
ES2181673T3 (es) | 1991-05-01 | 2003-03-01 | Jackson H M Found Military Med | Procedimiento de tratamiento de las enfermedades respiratorias infecciosas. |
DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
GB9112536D0 (en) | 1991-06-11 | 1991-07-31 | Celltech Ltd | Chemical compounds |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
GB9115364D0 (en) | 1991-07-16 | 1991-08-28 | Wellcome Found | Antibody |
US5843749A (en) | 1991-07-26 | 1998-12-01 | Regeneron Pharmaceuticals, Inc. | Ehk and Ror tyrosine kinases |
CA2078539C (en) | 1991-09-18 | 2005-08-02 | Kenya Shitara | Process for producing humanized chimera antibody |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
US5912015A (en) | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
GB9225453D0 (en) | 1992-12-04 | 1993-01-27 | Medical Res Council | Binding proteins |
US5934272A (en) | 1993-01-29 | 1999-08-10 | Aradigm Corporation | Device and method of creating aerosolized mist of respiratory drug |
US5885573A (en) | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
US6180377B1 (en) | 1993-06-16 | 2001-01-30 | Celltech Therapeutics Limited | Humanized antibodies |
UA40577C2 (uk) | 1993-08-02 | 2001-08-15 | Мерк Патент Гмбх | Біспецифічна молекула, що використовується для лізису пухлинних клітин, спосіб її одержання, моноклональне антитіло (варіанти), фармацевтичний препарат, фармацевтичний набір (варіанти), спосіб видалення пухлинних клітин |
ATE252894T1 (de) | 1995-01-05 | 2003-11-15 | Univ Michigan | Oberflächen-modifizierte nanopartikel und verfahren für ihre herstellung und verwendung |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US6019968A (en) | 1995-04-14 | 2000-02-01 | Inhale Therapeutic Systems, Inc. | Dispersible antibody compositions and methods for their preparation and use |
US6265150B1 (en) | 1995-06-07 | 2001-07-24 | Becton Dickinson & Company | Phage antibodies |
JP2000507912A (ja) | 1995-08-31 | 2000-06-27 | アルカームズ コントロールド セラピューティックス,インコーポレイテッド | 作用剤の徐放性組成物 |
US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
US5942328A (en) | 1996-02-29 | 1999-08-24 | International Business Machines Corporation | Low dielectric constant amorphous fluorinated carbon and method of preparation |
ES2395214T3 (es) | 1996-03-04 | 2013-02-11 | The Penn State Research Foundation | Materiales y métodos para aumentar la internalización celular |
US5985309A (en) | 1996-05-24 | 1999-11-16 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
US5874064A (en) | 1996-05-24 | 1999-02-23 | Massachusetts Institute Of Technology | Aerodynamically light particles for pulmonary drug delivery |
US5855913A (en) | 1997-01-16 | 1999-01-05 | Massachusetts Instite Of Technology | Particles incorporating surfactants for pulmonary drug delivery |
US5922845A (en) | 1996-07-11 | 1999-07-13 | Medarex, Inc. | Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies |
CA2260752A1 (en) | 1996-07-23 | 1998-01-29 | Tanox Pharma B.V. | Induction of t cell tolerance using a soluble molecule that can simultaneously block two costimulatory pathways |
WO1998006749A2 (en) | 1996-08-16 | 1998-02-19 | President And Fellows Of Harvard College | Soluble monovalent and multivalent mhc class ii fusion proteins, and uses therefor |
EP0826696B1 (de) | 1996-09-03 | 2002-05-29 | GSF-Forschungszentrum für Umwelt und Gesundheit GmbH | Verwendung bi-und trispezifischer Antikörper zur Induktion einer Tumorimmunität |
WO1998031346A1 (en) | 1997-01-16 | 1998-07-23 | Massachusetts Institute Of Technology | Preparation of particles for inhalation |
ATE427966T1 (de) | 1997-02-11 | 2009-04-15 | Immunomedics Inc | Stimulation einer immunantwort durch antikírper, welche mit dem alpha-galaktosylepitop markiert sind |
US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
DE19725586C2 (de) * | 1997-06-17 | 1999-06-24 | Gsf Forschungszentrum Umwelt | Verfahren zur Herstellung von Zellpräparaten zur Immunisierung mittels heterologer intakter bispezifischer und/oder trispezifischer Antikörper |
US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
SE512663C2 (sv) | 1997-10-23 | 2000-04-17 | Biogram Ab | Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer |
JP2002504342A (ja) | 1998-02-19 | 2002-02-12 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 一価mhc結合ドメイン融合タンパク質および接合体、多価mhc結合ドメイン融合タンパク質および接合体、ならびに多量体mhc結合ドメイン融合タンパク質および接合体、そしてそれらのための使用 |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
DE19819846B4 (de) | 1998-05-05 | 2016-11-24 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Multivalente Antikörper-Konstrukte |
GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
ATE238768T1 (de) | 1998-06-24 | 2003-05-15 | Advanced Inhalation Res Inc | Grosse poröse partikel ausgestossen von einem inhalator |
WO2000018806A1 (de) | 1998-09-25 | 2000-04-06 | Horst Lindhofer | Bispezifische und trispezifische antikörper, die spezifisch mit induzierbaren oberflächenantigenen als operationelle zielstrukturen reagieren |
ATE255420T1 (de) | 1998-09-25 | 2003-12-15 | Horst Lindhofer | Verwendung von tumorzellen zeitversetzt in kombination mit intakten antikörpern zur immunisierung |
US20030187196A1 (en) | 1998-12-30 | 2003-10-02 | Genentech, Inc. | Secreted and transmembrane polypeptides and nucleic acids encoding the same |
PL209786B1 (pl) | 1999-01-15 | 2011-10-31 | Genentech Inc | Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna |
ATE474931T1 (de) * | 2000-04-28 | 2010-08-15 | Mannkind Corp | Epitop-synchronisierung in antigen präsentierenden zellen |
US20040220388A1 (en) | 2000-06-30 | 2004-11-04 | Nico Mertens | Novel heterodimeric fusion proteins |
EP1319184B1 (en) | 2000-08-14 | 2007-07-25 | N.V. Organon | Use of antibodies against specific mhc-peptide complexes |
DE10043437A1 (de) | 2000-09-04 | 2002-03-28 | Horst Lindhofer | Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
JP3986439B2 (ja) | 2001-02-07 | 2007-10-03 | 中外製薬株式会社 | 造血器腫瘍の治療剤 |
US20050118164A1 (en) | 2001-03-09 | 2005-06-02 | William Herman | Targeted ligands |
CN1294148C (zh) | 2001-04-11 | 2007-01-10 | 中国科学院遗传与发育生物学研究所 | 环状单链三特异抗体 |
ITRM20010408A1 (it) | 2001-07-10 | 2003-01-10 | Univ Napoli Federico Ii | Mini-anticorpo umano citotossico per cellule tumorali che esprimono il recettore erbb2. |
US6833441B2 (en) | 2001-08-01 | 2004-12-21 | Abmaxis, Inc. | Compositions and methods for generating chimeric heteromultimers |
ES2276735T3 (es) | 2001-09-14 | 2007-07-01 | Affimed Therapeutics Ag | Anticuerpos fv multimericos de cadena sencilla en tandem. |
WO2003024191A2 (en) | 2001-09-21 | 2003-03-27 | Raven Biotechnologies, Inc. | Antibodies that bind to cancer-associated antigen cytokeratin 8 and methods of use thereof |
WO2003032814A2 (en) | 2001-10-16 | 2003-04-24 | Raven Biotechnologies, Inc. | Antibodies that bind to cancer-associated antigen cd46 and methods of use thereof |
MXPA04003798A (es) | 2001-10-25 | 2004-07-30 | Genentech Inc | Composiciones de glicoproteina. |
GB0126378D0 (en) | 2001-11-02 | 2002-01-02 | Oxford Biomedica Ltd | Antigen |
US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
NZ535425A (en) | 2002-03-13 | 2008-05-30 | Biogen Idec Inc | Anti-alphavbeta6 antibodies |
EP1492870A4 (en) | 2002-04-12 | 2005-08-03 | Raven Biotechnologies Inc | ANTIBODIES BINDING TO INTEGRIN-ALPHA-V-BETA-6 AND METHOD OF USE THEREOF |
US20040048319A1 (en) | 2002-05-03 | 2004-03-11 | Mather Jennie P. | ALCAM and ALCAM modulators |
ATE525398T1 (de) | 2002-05-10 | 2011-10-15 | Medimmune Inc | Epha2 monoklonale antikörper und deren anwendungsverfahren |
BR0311471A (pt) | 2002-05-30 | 2007-04-27 | Macrogenics Inc | anticorpo anti-cd16a, e, métodos de redução de uma resposta imune deletéria em um mamìfero e de tratamento de uma resposta imune deletéria em um mamìfero |
US7405061B2 (en) | 2002-11-13 | 2008-07-29 | Raven Biotechnologies, Inc. | Antigen PIPA and antibodies that bind thereto |
US7960512B2 (en) | 2003-01-09 | 2011-06-14 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
ES2897506T3 (es) | 2003-01-09 | 2022-03-01 | Macrogenics Inc | Identificación y modificación de anticuerpos con regiones Fc variantes y métodos de utilización de los mismos |
WO2005028498A2 (en) | 2003-09-18 | 2005-03-31 | Raven Biotechnologies, Inc. | Kid3 and kid3 antibodies that bind thereto |
CA2544532C (en) | 2003-11-28 | 2015-06-16 | Micromet Ag | Compositions comprising polypeptides |
US7235641B2 (en) | 2003-12-22 | 2007-06-26 | Micromet Ag | Bispecific antibodies |
EP1709081B1 (en) | 2004-01-16 | 2011-04-06 | Regeneron Pharmaceuticals, Inc. | Fusion polypeptides capable of activating receptors |
WO2006107617A2 (en) | 2005-04-06 | 2006-10-12 | Ibc Pharmaceuticals, Inc. | Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses |
CN100376599C (zh) * | 2004-04-01 | 2008-03-26 | 北京安波特基因工程技术有限公司 | 基因工程重组抗cea抗cd3抗cd28线性单链三特异抗体 |
US7378504B2 (en) | 2004-06-03 | 2008-05-27 | Medarex, Inc. | Human monoclonal antibodies to Fc gamma receptor I (CD64) |
KR101295139B1 (ko) | 2004-06-07 | 2013-08-12 | 레이븐 바이오테크놀로지스, 인코퍼레이티드 | 트랜스페린 리셉터 항체 |
ES2329269T3 (es) | 2004-08-18 | 2009-11-24 | Vib Vzw | Modulacion del numero de celulas de una planta. |
WO2006031653A2 (en) | 2004-09-10 | 2006-03-23 | Wyeth | Humanized anti-5t4 antibodies and anti-5t4 antibody / calicheamicin conjugates |
EP1794288A1 (en) | 2004-09-13 | 2007-06-13 | VIB vzw | The modulation of phagocytosis in neurons |
CA2587766A1 (en) | 2004-11-10 | 2007-03-01 | Macrogenics, Inc. | Engineering fc antibody regions to confer effector function |
BG65954B1 (bg) | 2005-01-05 | 2010-07-30 | Чавдар ВАСИЛЕВ | Средство за селективно подтискане активността на патологични автореактивни в-клетки |
WO2006076584A2 (en) | 2005-01-12 | 2006-07-20 | Raven Biotechnologies, Inc. | Kid31 and antibodies that bind thereto |
WO2006083852A2 (en) | 2005-01-31 | 2006-08-10 | Raven Biotechnologies, Inc. | Luca2 and antibodies that bind thereto |
WO2006084078A2 (en) | 2005-02-02 | 2006-08-10 | Raven Biotechnologies, Inc. | Jam-3 and antibodies that bind thereto |
NZ556561A (en) | 2005-02-02 | 2011-08-26 | Macrogenics West Inc | Adam-9 modulators |
AU2006210606B2 (en) | 2005-02-03 | 2012-03-22 | Macrogenics West, Inc. | Antibodies to Oncostatin M receptor |
KR101363252B1 (ko) | 2005-02-04 | 2014-02-13 | 레이븐 바이오테크놀로지스, 인코퍼레이티드 | Epha2에 결합하는 항체 및 그것의 사용방법 |
AU2006232310B9 (en) | 2005-04-06 | 2011-07-21 | Ibc Pharmaceuticals, Inc. | Improved stably tethered structures of defined compositions with multiple functions or binding specificities |
US9963510B2 (en) | 2005-04-15 | 2018-05-08 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
US9284375B2 (en) * | 2005-04-15 | 2016-03-15 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
EP1868650B1 (en) | 2005-04-15 | 2018-10-03 | MacroGenics, Inc. | Covalent diabodies and uses thereof |
WO2006133145A2 (en) * | 2005-06-06 | 2006-12-14 | Caprion Pharmaceuticals, Inc. | Tat-007 and methods of assessing and treating cancer |
CN104072614B (zh) | 2005-07-08 | 2017-04-26 | 生物基因Ma公司 | 抗-αvβ6 抗体及其用途 |
ES2526811T3 (es) | 2005-08-10 | 2015-01-15 | Macrogenics, Inc. | Identificación y modificación de anticuerpos con regiones Fc variantes y métodos de uso de estos |
JP2012228248A (ja) * | 2005-08-19 | 2012-11-22 | Abbott Lab | 二重可変ドメイン免疫グロブリン及びその使用 |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
WO2007024715A2 (en) | 2005-08-19 | 2007-03-01 | Abbott Laboratories | Dual variable domain immunoglobin and uses thereof |
CA2607056C (en) | 2005-10-19 | 2015-11-24 | Ibc Pharmaceuticals, Inc. | Methods and compositions for generating bioactive assemblies of increased complexity and uses |
CA2633486C (en) | 2005-12-16 | 2015-02-03 | Ibc Pharmaceuticals, Inc. | Multivalent immunoglobulin-based bioactive assemblies |
MX2008010561A (es) * | 2006-02-15 | 2009-03-02 | Imclone Systems Inc | Anticuerpos funcionales. |
EP1820513A1 (en) | 2006-02-15 | 2007-08-22 | Trion Pharma Gmbh | Destruction of tumor cells expressing low to medium levels of tumor associated target antigens by trifunctional bispecific antibodies |
MX2008011492A (es) | 2006-03-10 | 2008-09-22 | Wyeth Corp | Anticuerpos anti-5t4 y usos de los mismos. |
WO2007106707A2 (en) | 2006-03-10 | 2007-09-20 | Macrogenics, Inc. | Identification and engineering of antibodies with variant heavy chains and methods of using same |
US8409577B2 (en) | 2006-06-12 | 2013-04-02 | Emergent Product Development Seattle, Llc | Single chain multivalent binding proteins with effector function |
AT503889B1 (de) | 2006-07-05 | 2011-12-15 | Star Biotechnologische Forschungs Und Entwicklungsges M B H F | Multivalente immunglobuline |
AT503902B1 (de) | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von immunglobulinen |
WO2008027236A2 (en) | 2006-08-30 | 2008-03-06 | Genentech, Inc. | Multispecific antibodies |
CA2660795C (en) | 2006-09-18 | 2014-11-18 | Xencor, Inc. | Optimized antibodies that target hm1.24 |
WO2008143708A2 (en) | 2006-12-07 | 2008-11-27 | Mayo Foundation For Medical Education And Research | Methods and materials related to anti-amyloid antibodies |
WO2008140603A2 (en) | 2006-12-08 | 2008-11-20 | Macrogenics, Inc. | METHODS FOR THE TREATMENT OF DISEASE USING IMMUNOGLOBULINS HAVING FC REGIONS WITH ALTERED AFFINITIES FOR FCγR ACTIVATING AND FCγR INHIBITING |
WO2008145142A1 (en) | 2007-05-31 | 2008-12-04 | Genmab A/S | Stable igg4 antibodies |
JP2010190572A (ja) | 2007-06-01 | 2010-09-02 | Sapporo Medical Univ | IL13Ra2に対する抗体およびこれを含む診断・治療薬 |
CA2691434C (en) | 2007-06-21 | 2020-07-21 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
EP2014680A1 (en) | 2007-07-10 | 2009-01-14 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives |
WO2009029342A2 (en) * | 2007-07-13 | 2009-03-05 | The Johns Hopkins University | B7-dc variants |
EP2626371A1 (en) | 2007-07-31 | 2013-08-14 | MedImmune, LLC | Multispecific epitope binding proteins and uses thereof |
AU2008296361B2 (en) * | 2007-09-04 | 2013-04-11 | Compugen, Ltd. | Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics |
KR101759457B1 (ko) | 2007-12-21 | 2017-07-31 | 메디뮨 리미티드 | 인터루킨-4 수용체 알파(IL-4Rα)에 대한 결합 구성원-173 |
EP2113255A1 (en) | 2008-05-02 | 2009-11-04 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Cytotoxic immunoglobulin |
EP2328934A4 (en) | 2008-08-26 | 2013-04-03 | Macrogenics Inc | T cell Receptor Antibodies and Method of Use |
WO2010028796A1 (en) | 2008-09-10 | 2010-03-18 | F. Hoffmann-La Roche Ag | Trispecific hexavalent antibodies |
WO2010028795A1 (en) | 2008-09-10 | 2010-03-18 | F. Hoffmann-La Roche Ag | Multivalent antibodies |
WO2010028797A1 (en) | 2008-09-10 | 2010-03-18 | F. Hoffmann-La Roche Ag | Multivalent antibodies |
RU2744176C2 (ru) | 2008-12-19 | 2021-03-03 | Макродженикс, Инк. | Ковалентные диантитела и их применение |
MY152068A (en) | 2009-03-20 | 2014-08-15 | Genentech Inc | Bispecific anti-her antibodies |
EP2241576A1 (en) | 2009-04-17 | 2010-10-20 | Trion Pharma Gmbh | Use of trifunctional bispecific antibodies for the treatment of tumors associated with CD133+/EpCAM+ cancer stem cells |
EP2421899B1 (en) | 2009-04-23 | 2016-06-08 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Anti-human ror1 antibodies |
TW201100543A (en) | 2009-05-27 | 2011-01-01 | Hoffmann La Roche | Tri-or tetraspecific antibodies |
MX342623B (es) | 2009-06-26 | 2016-10-06 | Regeneron Pharma | Anticuerpos biespecificos facilmente aislados con formato de inmunoglobulina original. |
US8277919B2 (en) | 2009-07-23 | 2012-10-02 | VMO Systems, Inc. | Reflective coating for an optical disc |
IN2012DN01663A (es) | 2009-09-16 | 2015-06-05 | Immunomedics Inc | |
US20110070227A1 (en) | 2009-09-18 | 2011-03-24 | Anna-Marie Novotney-Barry | Treatment of Autoimmune and Inflammatory Diseases |
AR078470A1 (es) | 2009-10-02 | 2011-11-09 | Sanofi Aventis | Anticuerpos que se unen especificamente al receptor epha2 |
US20120294874A1 (en) | 2009-11-19 | 2012-11-22 | Paul Anthony Macary | Method for Producing T Cell Receptor-Like Monoclonal Antibodies and Uses Thereof |
GB201000467D0 (en) | 2010-01-12 | 2010-02-24 | Ucb Pharma Sa | Antibodies |
PT2361936T (pt) | 2010-02-25 | 2016-07-15 | Affimed Gmbh | Molécula que se liga a antigénio e utilizações desta |
US20110206672A1 (en) | 2010-02-25 | 2011-08-25 | Melvyn Little | Antigen-Binding Molecule And Uses Thereof |
CN106279416B (zh) | 2010-03-04 | 2019-08-30 | 宏观基因有限公司 | 与b7-h3反应性的抗体、其免疫学活性片段及其用途 |
EP2560683B2 (en) | 2010-04-23 | 2022-07-20 | F. Hoffmann-La Roche AG | Production of heteromultimeric proteins |
WO2011163401A2 (en) | 2010-06-22 | 2011-12-29 | Neogenix Oncology, Inc. | Colon and pancreas cancer specific antigens and antibodies |
US20130115215A1 (en) | 2010-07-14 | 2013-05-09 | Hongxing Zhou | Domain insertion immunoglobulin |
EP2407487A1 (en) * | 2010-07-14 | 2012-01-18 | F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. | Multispecific modular antibody |
CN103154025B (zh) * | 2010-08-02 | 2015-07-01 | 宏观基因有限公司 | 共价双抗体及其用途 |
CA2818992C (en) | 2010-12-01 | 2021-05-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric rabbit/human ror1 antibodies |
GB201020995D0 (en) * | 2010-12-10 | 2011-01-26 | Bioinvent Int Ab | Biological materials and uses thereof |
WO2012088290A2 (en) | 2010-12-22 | 2012-06-28 | Abbott Laboratories | Tri-variable domain binding proteins and uses thereof |
HUE031017T2 (en) | 2011-04-01 | 2017-06-28 | Wyeth Llc | Antibody Drug Conjugates |
WO2012156430A1 (en) | 2011-05-17 | 2012-11-22 | Trion Research Gmbh | Vaccine preparation containing trifunctional antibodies with antigen immunogenicity enhancer properties |
JP6145088B2 (ja) | 2011-05-21 | 2017-06-07 | マクロジェニクス,インコーポレーテッド | 脱免疫化血清結合ドメイン及び血清半減期を延長するためのその使用 |
SG10201509588TA (en) | 2011-05-21 | 2015-12-30 | Macrogenics Inc | CD3-Binding Molecules Capable Of Binding To Human And Non-Human CD3 |
CA2837169C (en) | 2011-05-24 | 2021-11-09 | Zyngenia, Inc. | Multispecific complexes comprising angiopoietin-2-binding peptide and their uses |
WO2012162583A1 (en) | 2011-05-26 | 2012-11-29 | Ibc Pharmaceuticals, Inc. | Design and construction of novel multivalent antibodies |
WO2012167067A1 (en) | 2011-06-03 | 2012-12-06 | Kraft Foods Global Brands Llc | Snacks from cheese |
WO2013003652A1 (en) | 2011-06-28 | 2013-01-03 | Sea Lane Biotechnologies, Llc | Multispecific stacked variable domain binding proteins |
US20140155581A1 (en) | 2011-07-06 | 2014-06-05 | Medimmune, Llc | Methods For Making Multimeric Polypeptides |
UA117901C2 (uk) * | 2011-07-06 | 2018-10-25 | Ґенмаб Б.В. | Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування |
AU2011373925B2 (en) | 2011-07-22 | 2016-04-28 | Affimed Therapeutics Ag | Multivalent antigen-binding Fv molecule |
EP2758438A1 (en) | 2011-09-23 | 2014-07-30 | Amgen Research (Munich) GmbH | Bispecific binding molecules for 5t4 and cd3 |
US9580509B2 (en) | 2011-11-07 | 2017-02-28 | Medimmune, Llc | Multispecific and multivalent binding proteins and uses thereof |
WO2013068874A1 (en) | 2011-11-11 | 2013-05-16 | Pfizer Inc. | Antibody-drug conjugates |
AU2013216943B2 (en) | 2012-02-10 | 2018-04-19 | Research Corporation Technologies, Inc. | Fusion proteins comprising immunoglobulin constant domain-derived scaffolds |
WO2013163427A1 (en) | 2012-04-25 | 2013-10-31 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Antibodies to treat hiv-1 infection |
CA2869529A1 (en) | 2012-05-24 | 2013-11-28 | Raffaella CASTOLDI | Multispecific antibodies |
EP2869845B1 (en) * | 2012-07-06 | 2019-08-28 | Genmab B.V. | Dimeric protein with triple mutations |
US20150203591A1 (en) | 2012-08-02 | 2015-07-23 | Regeneron Pharmaceuticals, Inc. | Mutivalent antigen-binding proteins |
JP2016503295A (ja) | 2012-11-07 | 2016-02-04 | ファイザー・インク | 抗il−13受容体アルファ2抗体および抗体−薬物コンジュゲート |
WO2014116846A2 (en) | 2013-01-23 | 2014-07-31 | Abbvie, Inc. | Methods and compositions for modulating an immune response |
EP2840091A1 (en) * | 2013-08-23 | 2015-02-25 | MacroGenics, Inc. | Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof |
EP2839842A1 (en) * | 2013-08-23 | 2015-02-25 | MacroGenics, Inc. | Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof |
EP2930188A1 (en) | 2014-04-13 | 2015-10-14 | Affimed Therapeutics AG | Trifunctional antigen-binding molecule |
RU2718692C2 (ru) | 2014-05-29 | 2020-04-13 | Мэкроудженикс, Инк. | Триспецифичные связывающие молекулы, которые специфически связывают антигены множества злокачественных опухолей, и способы их применения |
SG11201706024YA (en) * | 2015-01-26 | 2017-08-30 | Macrogenics Inc | Multivalent molecules comprising dr5-binding domains |
TWI773646B (zh) * | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
MX2018001227A (es) * | 2015-07-30 | 2018-03-26 | Macrogenics Inc | Moleculas de union a pd-1 y metodos de uso de las mismas. |
EP3337507A4 (en) * | 2015-08-17 | 2019-04-24 | MacroGenics, Inc. | BISPECIFIC MONOVALENT DIANTIBERS CAPABLE OF BINDING TO B7-H3 AND CD3 AND USES THEREOF |
EP3585431A4 (en) * | 2017-02-24 | 2020-12-16 | MacroGenics, Inc. | BISPECIFIC BINDING MOLECULES CAPABLE OF BINDING TO CD137 AND TUMOR ANTIGENS, AND THEIR USES |
AU2018385409A1 (en) | 2017-12-12 | 2020-07-02 | Macrogenics Inc. | Bispecific CD 16-binding molecules and their use in the treatment of disease |
US11685781B2 (en) | 2018-02-15 | 2023-06-27 | Macrogenics, Inc. | Variant CD3-binding domains and their use in combination therapies for the treatment of disease |
EP3794027A4 (en) | 2018-05-18 | 2022-02-09 | MacroGenics, Inc. | OPTIMIZED GP41 BINDING MOLECULES AND ASSOCIATED USES |
-
2015
- 2015-05-29 RU RU2016151721A patent/RU2718692C2/ru active
- 2015-05-29 SG SG10201913680PA patent/SG10201913680PA/en unknown
- 2015-05-29 CN CN202110803628.5A patent/CN113416252A/zh active Pending
- 2015-05-29 BR BR112016027912-3A patent/BR112016027912A2/pt not_active IP Right Cessation
- 2015-05-29 JP JP2016570005A patent/JP6647222B2/ja active Active
- 2015-05-29 CN CN201580027889.5A patent/CN106573050B/zh active Active
- 2015-05-29 PE PE2016002398A patent/PE20170765A1/es not_active Application Discontinuation
- 2015-05-29 TW TW104117564A patent/TWI718098B/zh active
- 2015-05-29 TW TW108131956A patent/TWI742423B/zh active
- 2015-05-29 MX MX2016015479A patent/MX2016015479A/es unknown
- 2015-05-29 PL PL15799187T patent/PL3148580T3/pl unknown
- 2015-05-29 CA CA2950008A patent/CA2950008C/en active Active
- 2015-05-29 BR BR112016027893A patent/BR112016027893A2/pt not_active IP Right Cessation
- 2015-05-29 US US15/313,765 patent/US10633440B2/en active Active
- 2015-05-29 US US15/313,741 patent/US10647768B2/en active Active
- 2015-05-29 AP AP2016009586A patent/AP2016009586A0/en unknown
- 2015-05-29 WO PCT/US2015/033081 patent/WO2015184207A1/en active Application Filing
- 2015-05-29 NZ NZ726520A patent/NZ726520A/en unknown
- 2015-05-29 KR KR1020227004882A patent/KR20220025917A/ko active IP Right Grant
- 2015-05-29 PE PE2016002490A patent/PE20170766A1/es unknown
- 2015-05-29 ES ES15799237T patent/ES2890079T3/es active Active
- 2015-05-29 SG SG11201609912TA patent/SG11201609912TA/en unknown
- 2015-05-29 CN CN202110803661.8A patent/CN113549153A/zh active Pending
- 2015-05-29 TW TW110138455A patent/TW202208442A/zh unknown
- 2015-05-29 CA CA2950572A patent/CA2950572C/en active Active
- 2015-05-29 AU AU2015266880A patent/AU2015266880B2/en active Active
- 2015-05-29 KR KR1020167035705A patent/KR102355609B1/ko active IP Right Grant
- 2015-05-29 WO PCT/US2015/033076 patent/WO2015184203A1/en active Application Filing
- 2015-05-29 EP EP21185550.7A patent/EP3954703A3/en active Pending
- 2015-05-29 NZ NZ726514A patent/NZ726514A/en unknown
- 2015-05-29 SG SG11201609917PA patent/SG11201609917PA/en unknown
- 2015-05-29 EP EP15799187.8A patent/EP3148580B1/en active Active
- 2015-05-29 TW TW108132334A patent/TWI747041B/zh active
- 2015-05-29 EP EP15799237.1A patent/EP3152235B1/en active Active
- 2015-05-29 ES ES15799187T patent/ES2856839T3/es active Active
- 2015-05-29 JP JP2016569969A patent/JP6685934B2/ja active Active
- 2015-05-29 TW TW104117567A patent/TWI707872B/zh active
- 2015-05-29 CN CN201580029259.1A patent/CN106414497B/zh active Active
- 2015-05-29 AU AU2015266797A patent/AU2015266797C1/en active Active
- 2015-05-29 KR KR1020167035691A patent/KR102364383B1/ko active IP Right Grant
- 2015-05-29 PL PL15799237T patent/PL3152235T3/pl unknown
- 2015-05-29 TN TN2016000525A patent/TN2016000525A1/en unknown
- 2015-05-29 RU RU2020111366A patent/RU2020111366A/ru unknown
- 2015-05-29 EA EA201692504A patent/EA035419B9/ru not_active IP Right Cessation
- 2015-05-29 MX MX2016015398A patent/MX2016015398A/es unknown
- 2015-05-29 MA MA040069A patent/MA40069A/fr unknown
- 2015-05-29 SG SG10201913324PA patent/SG10201913324PA/en unknown
-
2016
- 2016-11-18 ZA ZA2016/07995A patent/ZA201607995B/en unknown
- 2016-11-24 MX MX2020014221A patent/MX2020014221A/es unknown
- 2016-11-25 CL CL2016003040A patent/CL2016003040A1/es unknown
- 2016-11-28 CL CL2016003050A patent/CL2016003050A1/es unknown
- 2016-11-28 PH PH12016502370A patent/PH12016502370A1/en unknown
- 2016-11-28 IL IL249269A patent/IL249269B/en active IP Right Grant
- 2016-11-28 IL IL249266A patent/IL249266B/en active IP Right Grant
- 2016-11-28 PH PH12016502369A patent/PH12016502369A1/en unknown
-
2018
- 2018-11-09 AU AU2018260975A patent/AU2018260975B2/en active Active
-
2019
- 2019-06-17 AU AU2019204236A patent/AU2019204236B2/en active Active
- 2019-10-21 JP JP2019192047A patent/JP2020072664A/ja active Pending
-
2020
- 2020-02-28 US US16/805,105 patent/US11697684B2/en active Active
- 2020-03-13 US US16/818,893 patent/US11820818B2/en active Active
- 2020-04-01 JP JP2020065872A patent/JP2020117520A/ja active Pending
-
2021
- 2021-01-19 JP JP2021006240A patent/JP2021073224A/ja active Pending
-
2023
- 2023-05-19 US US18/320,599 patent/US20240117036A1/en active Pending
- 2023-10-11 US US18/484,921 patent/US20240182559A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL249266B (en) | Trispecific molecules that bind multiple cancer antigens and methods of using them | |
IL254223A (en) | CD20 binding compounds and their uses | |
IL246693B2 (en) | Antibody molecules to tim-3 and their uses | |
IL273641B (en) | Specific binding molecules for il-21 and uses thereof | |
SG11201808289SA (en) | Binding molecules to cd38 and pd-l1 | |
IL266516A (en) | An antibody that binds specifically to cd66c and its use | |
PL3484488T3 (pl) | Cząsteczki wiążące antygeny i sposoby ich stosowania | |
PL3362480T3 (pl) | Przeciwciało specyficznie wiążące się z ERBB3 i jego zastosowanie |